Ticker brief
TGTX TG THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$53.93
1 day
-3.2%
14 days
+10.6%
mkt cap
$8.2B
signals 14d
40
authors 14d
18
crowd 14d
+0.1σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 51% mid · 21 pctile own 1y | IV/HV 0.95× |
| Skew — 25Δ RR 30d | +0.066 95 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +1.90 normal | 5-session Δ +0.09 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-08-05 (z=2.7) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now +0.15 (−1 bearish … +1 bullish)
Who spoke18
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 11 | +0.37 |
| @Omnitrader69 | C | -1.39 | 4 | +0.48 |
| @YYDSxjm | B | -0.51 | 3 | +0.68 |
| @2000STOCKMASTER | C | +1.05 | 3 | +0.60 |
| @Pharmdca | C | +0.82 | 2 | +0.43 |
| @kiantrades | C | +0.69 | 2 | +0.50 |
| @equitydd | C | -2.03 | 2 | +0.23 |
| @fj_nextstage | C | -2.18 | 2 | +0.30 |
| @gmorton512 | C | +0.15 | 2 | +0.15 |
| @markflowchatter | B | +2.00 | 1 | +0.50 |
| @RichardMoglen | B | -0.93 | 1 | +0.40 |
| @bioinvestor24 | A | -0.45 | 1 | +0.70 |
| @OpenOutcrier | C | · | 1 | +0.30 |
| @cfaryanoconnell | C | -1.48 | 1 | +0.00 |
| @ClassicRoy | C | -1.52 | 1 | +0.00 |
| @dennisc230 | C | -1.13 | 1 | +0.20 |
| @Biomaven | A | +1.79 | 1 | +0.70 |
| @SteveDJacobs | C | -1.22 | 1 | +0.20 |
Recent signals30of 40 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @gmorton512 | +0.00 | Points readers to TGTX's pipeline status without summarizing its implications. | — | tweet ↗ |
| 2026-08-28 | @gmorton512 | +0.30 | Watches a tight handle pattern in TGTX as volume dries up. | — | tweet ↗ |
| 2026-08-27 | @SteveDJacobs | +0.20 | Friday watchlist identifies the first six of many equal-weight stocks using technical-system badges. | -3.2% | tweet ↗ |
| 2026-08-26 | @YYDSxjm | +0.45 | Argues J&J could fund a $20–40B acquisition aligned with TGTX's therapeutic areas. | -2.0% | tweet ↗ |
| 2026-08-25 | @semodough | +0.40 | Highlights growing traction for TGTX's subcutaneous program as more important than rumor-driven value. | -2.7% | tweet ↗ |
| 2026-08-25 | @Biomaven | +0.70 | Argues the TGTX upside case is too conservative given quarterly dosing and possible efficacy advantages. | -2.7% | tweet ↗ |
| 2026-08-25 | @dennisc230 | +0.20 | Watchlist cites constructive chart patterns in NVDA, MA, and MU plus TGTX buyout chatter. | -2.7% | tweet ↗ |
| 2026-08-25 | @semodough | +0.30 | Says TGTX's subcutaneous optionality is becoming increasingly visible. | -2.7% | tweet ↗ |
| 2026-08-24 | @Omnitrader69 | +0.15 | Notes resilient TGTX trading while questioning claims that a buyout rumor merely pumped options. | -3.7% | tweet ↗ |
| 2026-08-24 | @ClassicRoy | +0.00 | Identifies options with increasing implied volatility. | -3.7% | tweet ↗ |
| 2026-08-24 | @cfaryanoconnell | +0.00 | Lists options with increasing implied volatility. | -3.7% | tweet ↗ |
| 2026-08-23 | @YYDSxjm | +0.75 | Presents a multi-year organic-growth and acquisition thesis with valuation scenarios. | -0.6% | tweet ↗ |
| 2026-08-22 | @equitydd | +0.15 | Lists the leading names in the IBD Top 50 ranking, with TVTX ranked first. | -0.6% | tweet ↗ |
| 2026-08-22 | @semodough | +0.40 | Jefferies presents a $98 upside scenario for TGTX, implying 84% upside. | -0.6% | tweet ↗ |
| 2026-08-22 | @semodough | +0.40 | Cites Cantor's patent and peak-sales model supporting an $80-$85 per-share valuation. | -0.6% | tweet ↗ |
| 2026-08-22 | @semodough | +0.70 | Argues subcutaneous Briumvi is an underappreciated growth driver that could double the addressable market. | -0.6% | tweet ↗ |
| 2026-08-22 | @semodough | +0.40 | Cowen raises its TGTX DCF price target to $75 from $50 after increasing revenue estimates. | -0.6% | tweet ↗ |
| 2026-08-21 | @fj_nextstage | +0.35 | Lists new and returning IBD50 constituents; ticker output capped at six. | -0.6% | tweet ↗ |
| 2026-08-21 | @fj_nextstage | +0.25 | Lists IBD50 additions and inferred technical reasons; capped at six tickers. | -0.6% | tweet ↗ |
| 2026-08-21 | @OpenOutcrier | +0.30 | Recaps positive and negative chatter and discrete catalysts across six stocks. | -0.6% | tweet ↗ |
| 2026-08-21 | @Omnitrader69 | +0.50 | Speculates BIIB is the most logical buyer of TGTX. | -0.6% | tweet ↗ |
| 2026-08-21 | @equitydd | +0.30 | Lists the morning's top gainers; capped at six tickers. | -0.6% | tweet ↗ |
| 2026-08-21 | @bioinvestor24 | +0.70 | Calls TGTX a very good company suffering remarkable neglect from biotech funds. | -0.6% | tweet ↗ |
| 2026-08-21 | @2000STOCKMASTER | +0.35 | Vague boast directed at fund managers implies a positive TGTX stance. | -0.6% | tweet ↗ |
| 2026-08-21 | @kiantrades | +0.65 | Excited ticker-specific reaction amplifies attention to TGTX. | -0.6% | tweet ↗ |
| 2026-08-21 | @Pharmdca | +0.60 | Retrospectively says the post-earnings dip was a buying opportunity. | -0.6% | tweet ↗ |
| 2026-08-21 | @RichardMoglen | +0.40 | Says TGTX stands out positively from a set of bubble charts. | -0.6% | tweet ↗ |
| 2026-08-21 | @2000STOCKMASTER | +0.65 | Ridicules TGTX short sellers, conveying a strong bullish stance. | -0.6% | tweet ↗ |
| 2026-08-21 | @semodough | +0.20 | Criticizes BIIB for not acquiring TGTX years earlier. | -0.6% | tweet ↗ |
| 2026-08-21 | @2000STOCKMASTER | +0.80 | Reiterates that investors should have been long TGTX. | -0.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.